The TRANS MICE Act bars the use of federal funds to conduct, support, or otherwise finance a class of animal experiments that alter an animal’s sex characteristics so the body “no longer correspond[s] to the biological sex” of the animal. The prohibition applies broadly to any ‘‘covered research’’ done on ‘‘qualified animals’’ and sweeps in both direct and indirect federal support.
This matters because the ban targets common experimental tools—hormone administration, surgeries, drug treatments and other interventions—that underlie lines of basic, translational, and preclinical research. The statutory language is short and categorical, leaving agencies, universities, and industry to interpret what ‘indirect’ funding and vague terms like ‘modify the physical appearance’ will mean in practice.
At a Glance
What It Does
The bill prohibits federal funds from being made available to conduct, support, or fund any research that uses interventions to alter a non‑human vertebrate so its body does not correspond to its biological sex. It covers direct grants and any indirect federal support.
Who It Affects
Researchers who use hormones, drugs, surgery, genetic or other interventions on mammals, birds, fish, reptiles, or amphibians will be directly affected; federal agencies that award grants or manage research budgets will have new compliance questions.
Why It Matters
The prohibition could stop or narrow many lines of basic and preclinical science that rely on manipulating sex characteristics, and it will force institutions to redesign compliance and funding flows to avoid triggering the ban.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
At its core the bill creates an absolute funding bar: federal dollars cannot be used to carry out or support experiments that change a non‑human vertebrate’s sex characteristics so the animal no longer corresponds to its biological sex. That bar is written broadly—“notwithstanding any other provision of law”—and applies to both direct and indirect financial support from the federal government.
The text does not limit the ban to particular agencies or programs; any federal funding stream is implicated.
The bill defines ‘‘covered research’’ using examples rather than limits: it explicitly includes studies that use drugs, hormones, surgery, or “other interventions” to disrupt development, inhibit natural bodily functions, or modify appearance. Those three categories are functionally expansive: they could capture endocrine manipulation experiments, surgical gonadectomies, pharmacologic blockades, genetic manipulations that alter sexual phenotype, and even cosmetic interventions that change secondary sex characteristics.Who is in and who is out turns on the bill’s definitions. ‘‘Qualified animals’’ means non‑human vertebrates—mammals, birds, fish, reptiles, and amphibians—except where the animal naturally changes sex during its life or naturally possesses both male and female reproductive organs.
That carve‑out protects research on sequential hermaphrodites and true hermaphrodites, but it does not protect invertebrates or species with naturally occurring intersex conditions that do not meet the statutory phrasing.Because the statute bans ‘‘indirect’’ funding as well as direct grants, the practical effect will reach beyond principal investigators. Shared core facilities, institutional salary support, federally funded training grants that subsidize a researcher’s time, and subawards could all become compliance risks.
The bill contains no transitional language, no agency implementing mechanism, and no definition of enforcement, so agencies and institutions would need to interpret the prohibition and decide how to apply it to awards, renewals, and ongoing studies.
The Five Things You Need to Know
The statute bars any federal funds—explicitly including both direct and indirect support—from being used for defined ‘‘covered research’’ on ‘‘qualified animals.’, ‘‘Covered research’’ is defined to include experiments using drugs, hormones, surgery, or other interventions to disrupt development, inhibit natural functions, or modify physical appearance so the animal no longer corresponds to its biological sex.
‘‘Qualified animal’’ is any non‑human vertebrate other than ‘‘excepted animals’’ and the bill expressly lists mammals, birds, fish, reptiles, and amphibians as included groups.
‘‘Excepted animals’’ are animals that naturally change sex during their lifetime or naturally possess both male and female reproductive organs; those animals are excluded from the funding ban.
The text contains no express grandfathering, enforcement mechanism, or guidance on how agencies should identify or police ‘‘indirect’’ funding, leaving major implementation questions unresolved.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This short section names the statute the ‘‘TRANS MICE Act.’
Absolute prohibition on federal funding for covered animal research
This provision is the operative ban: ‘‘notwithstanding any other provision of law,’’ no federal funds may be made available to conduct, support, or fund (directly or indirectly) any covered research on a qualified animal. The ‘‘notwithstanding’’ clause signals congressional intent to override conflicting statutes or prior agency rules, making the ban comprehensive across federal funding instruments. Because the language sweeps in indirect support, ordinary grant administration questions—like whether institutional overhead or shared core facilities count as federal support for a particular project—become central compliance issues for agencies and recipients.
Definitions: covered research, qualified animal, excepted animal
This section defines the key terms that set the prohibition’s scope. ‘‘Covered research’’ uses three example categories: disrupting development, inhibiting natural functions, and modifying appearance, and it lists methods—drugs, hormones, surgery, and other interventions—commonly used in animal experimentation. ‘‘Qualified animal’’ is any non‑human vertebrate not captured by the ‘‘excepted animal’’ carve‑out; the statute helpfully enumerates vertebrate groups (mammals, birds, fish, reptiles, amphibians). ‘‘Excepted animal’’ excludes species that naturally change sex or naturally have both reproductive organ types, which narrows the ban away from certain evolutionary and ecological studies but does not address organisms outside the vertebrate category or more ambiguous biological states.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Organizations and individuals seeking an explicit end to federally funded experiments that alter sex characteristics—those groups gain a statutory prohibition that aligns with their policy goals.
- Researchers studying species that naturally change sex or hermaphroditic species, who see a clear statutory carve‑out protecting their work from the ban.
- Private funders who wish to sponsor such animal research outside the federal system, because the ban pushes affected investigators toward non‑federal sources of support.
- Institutions that avoid politically sensitive research may benefit reputationally and face fewer donor or public pressures tied to such studies.
Who Bears the Cost
- Academic investigators in developmental endocrinology, reproductive biology, and related fields whose experiments use hormones, surgeries, or drugs to probe sex‑related biology will lose access to federal support for many projects.
- Federal research agencies (NIH, NSF, USDA, DoD and others) that must interpret and enforce a broad ban across programs will face new administrative burdens and potential conflicts with peer review processes.
- Universities and research hospitals that rely on federal overhead and shared facilities may need to restructure how they allocate costs and certify compliance, raising institutional compliance costs.
- Small biotech and preclinical firms using federally supported research or collaborating with federally funded labs could see project delays or funding gaps if animal work is deemed covered.
Key Issues
The Core Tension
The central dilemma is between a categorical policy choice—to prohibit federal support for a set of interventions because they are seen as ideologically objectionable—and the scientific principle that basic and preclinical research requires broad latitude to manipulate biological systems; the bill solves for a clear political objective but creates enforcement, definitional, and scientific trade‑offs with no built‑in mechanism to resolve them.
The bill’s economy of language masks difficult line‑drawing. Phrases like ‘‘no longer correspond to the biological sex’’ and ‘‘modify the physical appearance’’ are vague in laboratory contexts: does altering secondary sex characteristics count, and what threshold of change triggers the ban?
Genetic manipulations that shift sexual phenotype, pharmacologic suppression of gonadal hormones, and surgical removal of gonads are all plausible targets, but the statute gives agencies no criteria or examples to guide consistent determinations.
The ‘‘indirect’’ funding language is consequential and ambiguous. It could be read narrowly (subawards, subcontracts, explicitly tied resources) or broadly (institutional infrastructure and salary support funded by federal sources).
That ambiguity will create compliance risk for institutions, chill certain collaborations, and force agencies to develop monitoring and certification processes they do not currently have in statute. The absence of transitional or grandfathering language means ongoing studies could be disrupted midstream unless agencies adopt interim guidance or exemptions—neither of which the bill requires.
Finally, the carve‑out for species that naturally change sex or have both reproductive organs resolves some narrow ecological questions but leaves others open. The statute protects sequential hermaphrodites and hermaphrodites but says nothing about intersex conditions, developmental anomalies, or non‑vertebrate models that are widely used in genetics and toxicology.
That selective scope raises practical and scientific tensions about which legitimate lines of inquiry Congress intended to preserve.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.